arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

IDEAYA Biosciences, Inc.

IDYA
$39.72 ▲ +0.85 (+2.17%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
36 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
24
Health
Poor
Bearish
auto_awesome

Analytical Summary

IDEAYA Biosciences, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $3.7B
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -8.1%
FCF / Share $-0.97
Trailing P/E
Price / Book 3.2x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 22, 2026.

36-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$8.86M
↑ +35.0%
Net Income Profit after all expenses
$-112.45M
↓ -45.1%
Operating Margin Operating profit as % of sales
52.2%
↑ +112.5% 3th
FCF / Share Free cash flow per share
$-0.97
↓ -35.6%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
5
Returns
34
Cash Quality
46

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 10 years · 36 quarters